Summary
• Skye Bioscience, Inc. (SKYE) stock rises 6% in pre-market trading, priced at $1.39 after closing at $1.31.
• Attention on class action lawsuits prompts investor interest, with deadlines for potential claims increasing media focus.
• Despite the recent gain, SKYE’s year-to-date decline stands at 46%, facing ongoing downward pressure and technical challenges.
SKYE Bioscience, Inc. (SKYE) is witnessing notable momentum in pre-market trading, currently priced at $1.39, marking a 6% increase from its last close of $1.31. The stock appears to be responding to developments surrounding a class action lawsuit, although no new catalysts have emerged in the last 24 hours.
Class Action Lawsuit Developments
Investors are currently focused on multiple announcements regarding class action lawsuits related to Skye Bioscience. The Rosen Law Firm has raised awareness of a January 16, 2026, lead plaintiff deadline for those who purchased SKYE securities between November 4, 2024, and October 3, 2025. This has led to increased media attention as stakeholders evaluate their legal options against the backdrop of potential compensation avenues without any upfront costs.
In a related note, Bronstein, Gewirtz & Grossman LLC informed investors about a class action lawsuit filed against Skye Bioscience and its officers, inviting those with substantial losses to consider their participation.
Market Data Snapshot
Despite the recent uptick, SKYE has been under significant pressure, reflected in its year-to-date performance of a 46% decline. The stock’s 52-week high stands nearly 77% lower, further illustrating the stock’s struggles over the last year. Presently, the stock has a Relative Strength Index (RSI) of 39.44, indicating it may be approaching oversold conditions.
Average trading volume for the last 10 days is around 210,672 shares, notably lower than the average 3-month volume of 808,257 shares, suggesting decreased interest in trading SKYE around these legal issues.
Technical Overview
From a technical perspective, SKYE is facing significant downward pressure, as indicated by its 20-day simple moving average (SMA) at -6.14%. The stock’s trajectory has been downward trending, with quarterly and yearly performance particularly concerning, at -56.41% and -71.88%, respectively. The volatility measures over recent periods can be indicative of investor sentiment and market conditions, with a weekly volatility of 7.38%.
Closing Thoughts
With increased legal scrutiny and related announcements driving recent engagement, investors and traders will be monitoring how this activity influences stock performance moving forward. The stock now enters the upcoming session with heightened attention, as discussions around the ongoing class action lawsuits tap into the broader sentiment affecting SKYE shares.